Trial · NCT05713877
Melatonin for Treatment of Delirium in Critically Ill Adult Patients
NCT05713877, Phase 2, Recruiting, Ciusss de L'Est de l'Île de Montréal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Melatonin for Treatment of Delirium in Critically Ill Adult Patients. Trials, record NCT05713877. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05713877
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Melatonin for Treatment of Delirium in Critically Ill Adult Patients
- NCT number
- NCT05713877
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Conditions
- Delirium
- Interventions
- Melatonin, Placebo
- First posted
- 2023-02-06
- Last updated
- 2026-03-23
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility: Enrollment rate | 8 months | Average enrollment rate of participants per month. |
| Primary | Clinical: Duration of delirium | 14 days | Compare the average duration of an episode of delirium defined as the number of days with ICDSC score ≥4 between the 2 groups. |
| Secondary | Feasibility: Study adherence | 8 months | Proportion of administered doses in the prescribed dose administration window (between 19:00 and 23:00 hours) divided by total number of eligible study days. |
| Secondary | Feasibility: Consent rate | 8 months | Proportion of participants recruited among eligible patients. |
| Secondary | Clinical: Adverse events | 14 days | Incidence of adverse events reported in the Canadian melatonin monograph (i.e. headache and nausea) observed by the investigators or reported by the treating team. |
| Other | Feasibility: Completion of study | 8 months | Proportion of participants who completed the study and reasons associated with withdrawal. |
| Other | Feasibility: MDAS assessment time (minutes) | 8 months | Time required for the administration of the Memorial Delirium Assessment Scale (MDAS). Values from 0 to 30. A higher score means a worse outcome. |
| Other | Feasibility: Completion of ICDSC | 8 months | Proportion of missing data in the completion of the Intensive Care Delirium Screening Checklist (ICDSC). Values from 0 to 8. A higher score means a worse outcome. |
| Other | Clinical: Antipsychotics dose (mg) administered to participants | 14 days | Cumulative dose of de novo antipsychotics, reported in haloperidol equivalent dose, received by participants during delirium. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05713877
GET https://conductscience.org/api/trials/v1/NCT05713877/registered